Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence.
Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms.
Drug: naltrexone (Revia)
Drug: nicotine replacement patch
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
|Official Title:||Nalmefene in Nicotine and Alcohol Dependence|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000437
|United States, Florida|
|Department of Psychiatry, University of Miami School of Medicine|
|Miami, Florida, United States, 33136|
|Principal Investigator:||Barbara Mason, PhD||University of Miam|